Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
The work shows the effects of caffeine after the intrastriatal injection of 6-OHDA in rats, considered as a model of Parkinson disease (PD). Two weeks after the 6-OHDA lesion, rats exhibit a characteristic rotation behavior as a response to the apomorphine challenge. Our results showed significant increases in the number of apomorphine-induced rotations in 6-OHDA-lesioned rats, as compared to sham-operated animals. A partial recovery was observed in 6-OHDA-lesioned rats, after caffeine (10 and 20 mg/kg, i.p., daily for 14 days) treatment. The stereotaxic injection of 6-OHDA produced loss of striatal neurons, as indicated by the decrease in monoamines levels, in the ipsilateral side (75-85%) when compared to the contralateral side. Significant decreases in noradrenaline levels were seen in the ipsilateral side of 6-OHDA group (62%), and this effect was not significantly reversed in caffeine-treated groups. While significant decreases in dopamine levels were seen in the ipsilateral side of 6-OHDA group (78%), in the caffeine-treated group (10 and 20 mg/kg, i.p.) the decreases were only 53 and 18%, indicating significant recoveries. In conclusion, our data demonstrated beneficial effects of caffeine in this model of PD, suggesting the potential use of A2A antagonists as a novel treatment for this neurodegenerative disease.
Aguiar
Lissiana Magna Vasconcelos
LM
Federal University of Ceará, Brazil. lissiana_m@yahoo.com.br
Nobre
Hélio V
HV
Macêdo
Danielle S
DS
Oliveira
Aline A
AA
Freitas
Rivelilson M
RM
Vasconcelos
Silvânia M
SM
Cunha
Geanne M A
GM
Sousa
Francisca Cléa F
FC
Viana
Glauce Socorro B
GS
D000818:Animals; D001058:Apomorphine / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001927:Brain Diseases / Q000188:drug therapy; D002110:Caffeine / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016627:Oxidopamine / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar
D015259:Dopamine Agents; D018696:Neuroprotective Agents; D002110:Caffeine; D016627:Oxidopamine; D001058:Apomorphine